Posts by admin
Mesothelioma Diagnosis Rates Have Remained Stable even though Mesothelioma Survival has Improved
It was found that the number of pleural mesothelioma diagnoses has stayed the same, while the survival rate for people with the disease has slightly improved. Once asbestos was not used as much because of multiple regulations, the number of diagnoses of mesothelioma was predicted to go down. Instead, the number of diagnoses has remained…
Read MoreThe Ketogenic Diet Could be used to Slow Cancer Growth
According to a study done at The University of Texas at Dallas, the Ketogenic diet, which is very low in sugar, as well as the administration of a diabetes drug that prevents glucose in the blood from being adsorbed by the kidneys, slowed down the growth of squamous cell carcinoma tumors in mice. This specific…
Read MoreOpdivo and MTG201 Together Could Potentially Treat Mesothelioma
Typical cancer treatments are hard on the body and are not always effective. When treating someone for cancer, chemotherapy is typically used, which kills cancer cells or stops them from growing or spreading. Chemotherapy can also kill healthy cells, which makes it hard on the body. Immunotherapy is another option, and it works by helping…
Read MoreDendritic Cell Therapy Could be used to Treat Mesothelioma
Immunotherapy is a blossoming field that is becoming more advanced. Instead of other treatments that kill healthy cells in addition to killing cancerous cells, immunotherapy uses the body’s immune system to fight cancer cells, leaving healthy non-cancerous cells intact. It is a better treatment because it is very effective, more efficient, and is easier on…
Read MoreUsing a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Primary Outcome Measures Maximum tolerated dose [ Time Frame: up to 24 months ]A dose will be considered tolerable if there are no more than 2 out of 10 participants with dose limiting toxicities. Inclusion Criteria Age >/= 18 years Karnofsky performance status >/= 70% Pathologic diagnosis of malignant pleural mesothelioma at MSK Positive immunohistochemical staining for WT-1 Patients…
Read MoreWorld Lung Cancer Day, August 1, 2019
With over 200,000 new cases diagnosed each year, lung cancer is the most common and the leading cause of death from cancer in both men and women in the United States. The American Cancer Society projects over 140,000 people will die from lung cancer in 2019 and the majority of those diagnosed are 65 years…
Read MorePhase I Clinical Trial Yields Positive Results In Latest Immunotherapy Treatment
The immune system is the body’s first line of defense when fighting off any illness, attacking foreign organisms or other substances that may harm or threaten the over health of the body. When the immune system is compromised, the body is unable to fight infections and becomes weak as the illness takes over. For those…
Read MoreImpact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis (COCOON)
Primary Outcome Measures Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire [ Time Frame: 90 days ]State anxiety reflects the current emotional state, which allows the patient’s nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety). The patient must answer 20…
Read MoreTalcum Powder and Mesothelioma: A Criminal Investigation Against Johnson & Johnson
Talcum powder, commonly known as baby powder, is a product that absorbs moisture, prevents rashes and skin irritations, and keeps skin dry. Safe enough to use on delicate newborn skin, talcum powder has been a household staple for decades and many women have been using it for years for feminine hygiene. However, studies have shown…
Read MoreMTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells (REIC)/Dikkopf (Dkk)-3 gene, on Days 1, 8, 22, and 50. Patients will also receive every 4 weekly intravenous infusions of nivolumab, 480 mg, starting on Day 2. Safety and anti-tumor activity will be monitored at regular intervals throughout the study.
Read More